| 3.3 0.07 (2.17%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.95 |
1-year : | 4.62 |
| Resists | First : | 3.39 |
Second : | 3.95 |
| Pivot price | 3.15 |
|||
| Supports | First : | 3.11 |
Second : | 2.94 |
| MAs | MA(5) : | 3.24 |
MA(20) : | 3.14 |
| MA(100) : | 3.61  |
MA(250) : | 3.93 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 78.3 |
D(3) : | 75.2 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 5.55 | Low : | 2.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VYGR ] has closed below upper band by 12.0%. Bollinger Bands are 44.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.39 - 3.41 | 3.41 - 3.42 |
| Low: | 3.18 - 3.2 | 3.2 - 3.21 |
| Close: | 3.27 - 3.3 | 3.3 - 3.33 |
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Fri, 14 Aug 2026
Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares - Stock Titan
Wed, 12 Aug 2026
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47% - simplywall.st
Wed, 12 Aug 2026
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47% - Sahm
Mon, 10 Aug 2026
Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat
Mon, 10 Aug 2026
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Moomoo
Thu, 06 Aug 2026
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 4.321e+007 (%) |
| Held by Institutions | 15.1 (%) |
| Shares Short | 3,650 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1994e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 167.3 % |
| Return on Equity (ttm) | -27.1 % |
| Qtrly Rev. Growth | 3.649e+007 % |
| Gross Profit (p.s.) | -45.73 |
| Sales Per Share | -39.9 |
| EBITDA (p.s.) | -6.78321e+007 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -128 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 1.5 |
| Dividend | 0 |
| Forward Dividend | 3.84e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|